识别阿尔茨海默病生物标志物及其免疫功能表征
Mingkai Lin1,2, Yue Zhou1, Peixian Liang3
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Archives of medical science : AMS
|April 7, 2025
概括
这项研究使用多omics识别了阿尔茨海默病 (AD) 的五种生物标志物. 关键生物标志物RBM3,GOLGA8A和ALS2与CD8T细胞相关,表明它们在AD的诊断和预后价值.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样斑块和团.
- 了解AD机制和免疫特征对于诊断和治疗至关重要.
研究的目的:
- 研究阿尔茨海默病的分子机制和免疫特征.
- 使用多omics数据识别AD的新型诊断生物标志物.
主要方法:
- 使用了大量RNA测序 (RNA-seq) 和单细胞RNA测序 (scRNA-seq).
- 进行了差异表达分析,机器学习和免疫透分析.
主要成果:
- 鉴定出了五种潜在的AD生物标志物 (RBM3,GOLGA8A,ALS2,FSD2,LOC100287628).这些生物标志物包括:
- 在AD星球细胞中观察到生物标志物的明显表达模式.
- 在AD免疫微环境中,RBM3,GOLGA8A和ALS2与CD8T细胞透有很强的相关性.
结论:
- 已识别的生物标志物对阿尔茨海默病具有显著的诊断潜力.
- 星球细胞中RBM3的降低调节和减少CD8T细胞透是潜在的AD风险因素.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
734
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.7K
相关概念视频
01:26Alzheimer's Disease: Overview
342
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
342
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133